Education
About Us
Working with TipRanks
Follow Us
Cogstate Ltd (COGZF)
OTHER OTC:COGZF
COGZF Stock Chart & Stats
$1.55
$0.02(3.01%)
At close: 4:00 PM EST
$1.55
$0.02(3.01%)
Day’s Range― - ―
52-Week Range$0.74 - $2.10
Previous CloseN/A
Volume500.00
Average Volume (3M)1.10K
Market Cap
$266.93M
Enterprise Value$399.08M
Total Cash (Recent Filing)$51.06M
Total Debt (Recent Filing)$1.07M
Price to Earnings (P/E)14.0
Beta0.64
Next Earnings
Aug 26, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend Yield0.77%
Share Statistics
EPS (TTM)0.03
Shares Outstanding171,554,430
10 Day Avg. Volume1,514
30 Day Avg. Volume1,097
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)6.26
Price to Sales (P/S)5.90
P/FCF Ratio35.68
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue4.68
Enterprise Value/Gross Profit13.44
Enterprise Value/Ebitda16.55
Forecast
1Y Price Target
$2.13Price Target Upside37.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.05
Revenue Forecast (FY)$42.42M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & Low LeverageVery low leverage and a high equity ratio give Cogstate durable financial flexibility, allowing sustained funding for R&D, delivery capacity and optional capital returns without refinancing risk. Robust ROE indicates efficient capital use that supports long‑term strategic execution.
High Gross And Net MarginsConsistently strong gross and net margins demonstrate structural pricing power and operational efficiency, enabling the business to generate cash and absorb growth investments. High margins help sustain profitability through revenue cycles and fund technology and AI development.
Growing Backlog And Contracted RevenueA sizable and increasing backlog with higher forward contracted revenue provides multi‑period visibility into revenue conversion, enabling better resource planning and supporting anticipated margin recovery as contracted work converts to billings and operational leverage is realised.
Bears Say
Sharp Revenue & Free‑cash‑flow DeclinesA large year‑over‑year revenue drop and steep free cash flow decline materially reduce reinvestment capacity and increase sensitivity to timing of contract conversion. Even with strong margins, such declines constrain growth initiatives and heighten execution risk until cash flows stabilise.
Revenue Timing And Mix VolatilitySignificant timing skew from late‑signed contracts and variability in license fee recognition produces lumpy revenue and cash conversion. That structural volatility complicates forecasting, budgeting and margin comparability, making steady investment pacing and investor visibility harder.
Concentration Risk In Core Alzheimer TrialsHeavy exposure to large presymptomatic Alzheimer trials creates boom‑and‑bust cycles in demand and revenue; if major trials pause or end, utilisation and bookings can drop sharply. Diversification into other CNS areas reduces but does not eliminate this structural concentration risk.
Cogstate Ltd News
COGZF FAQ
What was Cogstate Ltd’s price range in the past 12 months?
Cogstate Ltd lowest stock price was $0.74 and its highest was $2.10 in the past 12 months.
What is Cogstate Ltd’s market cap?
Cogstate Ltd’s market cap is $266.93M.
When is Cogstate Ltd’s upcoming earnings report date?
Cogstate Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 168 days.
How were Cogstate Ltd’s earnings last quarter?
Cogstate Ltd released its earnings results on Feb 18, 2026. The company reported $0.026 earnings per share for the quarter, beating the consensus estimate of $0.021 by $0.005.
Is Cogstate Ltd overvalued?
According to Wall Street analysts Cogstate Ltd’s price is currently Undervalued.
Does Cogstate Ltd pay dividends?
Cogstate Ltd pays a Notavailable dividend of $0.013 which represents an annual dividend yield of 0.77%. See more information on Cogstate Ltd dividends here
What is Cogstate Ltd’s EPS estimate?
Cogstate Ltd’s EPS estimate is 0.04.
How many shares outstanding does Cogstate Ltd have?
Cogstate Ltd has 171,554,430 shares outstanding.
What happened to Cogstate Ltd’s price movement after its last earnings report?
Cogstate Ltd reported an EPS of $0.026 in its last earnings report, beating expectations of $0.021. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cogstate Ltd?
Currently, no hedge funds are holding shares in COGZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogstate Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.13 (37.35% Upside)
$2.13 (37.35% Upside)
Insider Transactions
Bought Shares
Worth AU$22.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
140.24%
12-Months-Change
Fundamentals
Return on Equity
26.76%
Trailing 12-Months
Asset Growth
12.30%
Trailing 12-Months
Company Description
Cogstate Ltd
Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
COGZF Company Deck
COGZF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and forward visibility: record new trial starts, a 105% jump in sales contracts, solid YoY revenue/backlog growth, expanding channel partnerships, and a healthy cash balance. Short‑term margin pressure and a $0.5M doubtful debt provision were acknowledged, largely driven by deliberate investments in delivery capacity, timing of contract recognition and one‑off adjustments. Management expects margins to recover in H2 as contracted revenue converts and maintains a clear strategy of diversification and technology investment to sustain medium‑term growth.View all COGZF earnings summariesCOGZF Stock 12 Month Forecast
Average Price Target
$2.13
▲(37.35% Upside)
Technical Analysis
―
Singular Health Group Ltd
―
Alcidion Group Limited
―
ImExHS Limited
―
PainChek Ltd
―
Ownership Overview
3.79% Insiders
0.45% Mutual Funds
<0.01% Other Institutional Investors
95.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---